Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Provides clinicians with information that can drive treatment decisions in patients with NSCLC.
The Resolution ctDx LungTM assay includes actionable genes for targeted FDA-approved therapies
or therapies in clinical trials.
CLINICAL RESPONSE DATA
In a prospective clinical study, the Resolution ctDx Lung assay demonstrated the following performance1:
97% (34/35) of patients who received plasma-directed therapy had a clinical and radiological response to the matched targeted therapy
46% (96/210) of patients had an oncogenic driver alteration detected, including actionable mutations in EGFR, ALK, MET, BRAF, ROS1, and RET
90% (60/67) positive concordance between plasma and tissue NGS testing. Sub-analysis demonstrated
96% (49/51) positive concordance within NCCN® oncogenic recognized driver alterations in lung cancer.
The Resolution ctDx Lung™ assay targets actionable, somatic SNVs, indels,
fusions, and copy number variants in 22 genes in NSCLC.2
Please see the test menu for additional specimen and test information.